EMA/789818/2018

European Medicines Agency decision

P/0391/2018

Of 7 December 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Janus Kinase-1 inhibitor (PF-04965842) (EMEA-002312-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

An agency of the European Union

European Medicines Agency decision

P/0391/2018

Of 7 December 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Janus Kinase-1 inhibitor (PF-04965842) (EMEA-002312-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Pfizer Ltd on 18 December 2017 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 October 2018, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for Janus Kinase-1 inhibitor (PF-04965842), tablet, age-appropriate oral liquid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for Janus Kinase-1 inhibitor (PF-04965842), tablet, age-appropriate oral liquid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for Janus Kinase-1 inhibitor (PF-04965842), tablet, age-appropriate oral liquid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Pfizer Ltd, Ramsgate Road, CT13 9NJ - Sandwich, United Kingdom.

EMA/PDCO/536175/2018
London, 19 October 2018

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-002312-PIP01-17

Scope of the application

Active substance(s):

Janus Kinase-1 inhibitor (PF-04965842)

Condition(s):

Treatment of atopic dermatitis

Pharmaceutical form(s):

Tablet

Age-appropriate oral liquid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Pfizer Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Pfizer Ltd submitted for agreement to the European Medicines Agency on 18 December 2017 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 23 January 2018.

Supplementary information was provided by the applicant on 13 July 2018. The applicant proposed modifications to the paediatric investigation plan.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of atopic dermatitis

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- tablet, age-appropriate oral liquid dosage form, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of atopic dermatitis

2.1.1. Indication(s) targeted by the PIP

Treatment of patients with moderate to severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to topical therapies or for whom these treatments are not appropriate

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Age-appropriate oral liquid dosage form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of an age-appropriate oral liquid dosage form suitable for patients younger from 2 years of age and older
Non-clinical studies	2	**Study 2** 2-week dose range-finding study in juvenile rats to evaluate tolerability of Janus Kinase-1 inhibitor (PF-04965842) and to inform dose selection for the definitive juvenile toxicity study

Area	Number of measures	Description
		Study 3 Definitive juvenile toxicity study in rats to evaluate body weight, femur length and weight, haematology, lymphoid organ weights (spleen, thymus), and microscopic examination (stifle joint, thymus, spleen, mesenteric lymph node, inguinal lymph node and/or gut-associated lymphoid tissue) Toxicokinetic evaluations to determine the systemic exposure of PF-04965842
Clinical studies	5	**Study 4** Double-blind, randomised, placebo-controlled, parallel group trial to evaluate efficacy and safety of Janus Kinase -1 inhibitor (PF-04965842) compared to placebo in adolescents (and adults) with moderate to severe atopic dermatitis (AD) **Study 5** Double-blind, randomised, placebo-controlled, parallel group trial to evaluate efficacy and safety of PF 04965842 compared to placebo in adolescents (and adults) with moderate to severe atopic dermatitis (AD) **Study 6** Double-blind, randomised, placebo-controlled, parallel group trial to evaluate efficacy and safety of PF 04965842 as add-on to topical treatment compared to placebo in children from 6 to less than 12 years of age with moderate to severe AD **Study 7** Double-blind, randomised, placebo-controlled, parallel group trial to evaluate efficacy and safety of PF 04965842 as add-on to topical treatment in a staggered approach compared to placebo in children from 2 to less than 6 years of age with moderate to severe AD **Study 8** Open-label, uncontrolled trial to evaluate long-term safety of PF 04965842 in children from 2 to less than 12 years of age who participated in Studies 6 and 7
Extrapolation, modelling and simulation studies	3	**Study 9** Population PK analysis and exposure-response modelling of efficacy measures in adult and adolescent patients with moderate to severe AD **Study 10** Population PK analysis in paediatric patients with moderate to severe

Area	Number of measures	Description
		AD **Study 11** Extrapolation of PK characteristics for determining starting dose in children from 2 years to less than 12 years of age
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes